Related Experiment Video
Updated: May 27, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease
Zhikun Dai1,2, Zihong Bao3, Hanyuan Lin2,4
1Department of Infectious Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, Guangdong, China.
Abstract:
Steatotic liver disease (SLD) is a common chronic liver disease without effective therapeutic options. Some studies suggest potential health benefits of dietary live microbes. This study aims to investigate the association between dietary live microbes intake and metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic alcohol-related liver disease (MetALD) / alcoholic liver disease (ALD) in adults. Data from the National Health and Nutrition Examination Survey 1999-2018 were analyzed. MASLD was defined according to the latest Delphi Consensus standard. Participants were grouped based on estimated dietary live microbe intake: low (< 104 CFU/g), moderate (104-107 CFU/g), and high (> 107 CFU/g). Multivariable logistic regression analysis was employed to assess the impact of dietary live microbes on MASLD/MetALD/ALD, along with further investigations into non-dietary probiotic/prebiotic relationships. Participants had a weighted mean age of 47.05 years (SE, 0.24) and 50.59% were female. MASLD proportions differ among low (21.76%), moderate (22.24%), and high (18.96%) microbe groups. Similarly, for MetALD, proportions are 7.75%, 6.95%, and 6.44%, and for ALD, 5.42%, 3.59%, and 2.97% in respective groups. The high dietary live microbe intake group was associated with a 16% lower risk of MASLD compared to those in the low intake group (trend test, P = 0.02), while the risk of ALD was reduced by 25% in the moderate intake group. A lack of association was identified between non-dietary prebiotic/probiotic and MASLD/MetALD/ALD. Our study suggests that a relatively high intake of live microbes diets in adults is associated with a lower risk of SLD.
Insights
High intake of dietary live microbes is linked to a reduced risk of steatotic liver disease (SLD). This includes metabolic dysfunction-associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD).
Area of Science:
- Gastroenterology and Hepatology
- Nutrition and Dietetics
- Microbiology
Background:
- Steatotic liver disease (SLD) is a prevalent chronic condition lacking effective treatments.
- Dietary live microbes are increasingly recognized for potential health benefits.
- Existing research necessitates investigation into the role of dietary live microbes in liver health.
Purpose of the Study:
- To examine the association between dietary live microbe consumption and liver disease prevalence.
- Specifically investigate links with metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic alcohol-related liver disease (MetALD), and alcoholic liver disease (ALD).
Main Methods:
- Analysis of National Health and Nutrition Examination Survey (NHANES) data from 1999-2018.
- Participants categorized into low, moderate, and high dietary live microbe intake groups (CFU/g).
- Multivariable logistic regression used to assess associations, controlling for confounders.
Main Results:
- High dietary live microbe intake was associated with a 16% reduced risk of MASLD (P=0.02).
- Moderate intake showed a 25% reduced risk of alcoholic liver disease (ALD).
- No significant association found between non-dietary prebiotics/probiotics and these liver conditions.
Conclusions:
- Higher dietary intake of live microbes correlates with a lower risk of steatotic liver disease in adults.
- Dietary interventions with live microbes may offer a potential strategy for SLD prevention.
- Further research is warranted to elucidate mechanisms and confirm clinical efficacy.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019